Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1071-1080 Newer>

Bio-IT World March 17, 2004	Blood, Sweat, and Tissue Genomics Collaborative and Ardais take the lead in using IT to bring human tissue banking into the era of clinical genomics.
Bio-IT World March 17, 2004	Strategic Insights Clinical Trials Major drug developers have put electronic data capture to the test and found benefits ranging from instant data access to fewer truckloads of paper. Yet many clinical sites are slow to accept the technology.
Bio-IT World March 17, 2004	Speeding EDC Adoption Implementation by clinical sites is lumbering along at an unimpressive rate. Here's what must be done to speed things up
Bio-IT World March 17, 2004 Kenneth Getz	Getting Past No Low adoption rates of e-clinical trial technology can't be blamed on external market dynamics alone. Biopharmas must face four inhibitors within their own organizations
Bio-IT World March 17, 2004 Paul Bleicher	Winning at EDC Implementation Adoption may be lagging at the enterprise level, but there's a stalwart group of biopharmas making EDC happen. Here's how they're doing it
Bio-IT World March 17, 2004	The Billion-Dollar Model Company to watch · GenPath takes a novel approach to cancer research
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
Bio-IT World March 17, 2004	IBM: Pedal to the Metal in Healthcare IBM now melds healthcare, life sciences, and IT.
BusinessWeek March 29, 2004 Gene G. Marcial	Recovery At MedImmune? Flu season is over, but it was a disaster for the No. 6 U.S. biotech, MedImmune (MEDI ). Its ballyhooed FluMist, a nasal-spray flu vaccine, was a flop -- which sent the stock reeling, from 42 in June to 23 now. As a result, some pros are buying: David Katz of Matrix Asset Advisors is confident MedImmune can turn FluMist around, by pricing it lower and educating doctors and consumers about the product.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
<Older 1071-1080 Newer> Return to current articles.